We have also made significant progress with GEO-MVA, our vaccine candidate for Mpox, and expect to achieve production of a cGMP clinical batch during the fourth quarter. With GEO-MVA, we intend to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback